269 related articles for article (PubMed ID: 25724305)
41. BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela.
Lara K; Consigliere N; Pérez J; Porco A
Biol Res; 2012; 45(2):117-30. PubMed ID: 23096355
[TBL] [Abstract][Full Text] [Related]
42. Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2.
Claes K; Poppe B; Machackova E; Coene I; Foretova L; De Paepe A; Messiaen L
Genes Chromosomes Cancer; 2003 Jul; 37(3):314-20. PubMed ID: 12759930
[TBL] [Abstract][Full Text] [Related]
43. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.
Meyer P; Voigtlaender T; Bartram CR; Klaes R
Hum Mutat; 2003 Sep; 22(3):259. PubMed ID: 12938098
[TBL] [Abstract][Full Text] [Related]
44. A Multiplex Homology-Directed DNA Repair Assay Reveals the Impact of More Than 1,000 BRCA1 Missense Substitution Variants on Protein Function.
Starita LM; Islam MM; Banerjee T; Adamovich AI; Gullingsrud J; Fields S; Shendure J; Parvin JD
Am J Hum Genet; 2018 Oct; 103(4):498-508. PubMed ID: 30219179
[TBL] [Abstract][Full Text] [Related]
45. Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms.
de la Hoya M; Soukarieh O; López-Perolio I; Vega A; Walker LC; van Ierland Y; Baralle D; Santamariña M; Lattimore V; Wijnen J; Whiley P; Blanco A; Raponi M; Hauke J; Wappenschmidt B; Becker A; Hansen TV; Behar R; Investigators K; Niederacher D; Arnold N; Dworniczak B; Steinemann D; Faust U; Rubinstein W; Hulick PJ; Houdayer C; Caputo SM; Castera L; Pesaran T; Chao E; Brewer C; Southey MC; van Asperen CJ; Singer CF; Sullivan J; Poplawski N; Mai P; Peto J; Johnson N; Burwinkel B; Surowy H; Bojesen SE; Flyger H; Lindblom A; Margolin S; Chang-Claude J; Rudolph A; Radice P; Galastri L; Olson JE; Hallberg E; Giles GG; Milne RL; Andrulis IL; Glendon G; Hall P; Czene K; Blows F; Shah M; Wang Q; Dennis J; Michailidou K; McGuffog L; Bolla MK; Antoniou AC; Easton DF; Couch FJ; Tavtigian S; Vreeswijk MP; Parsons M; Meeks HD; Martins A; Goldgar DE; Spurdle AB
Hum Mol Genet; 2016 Jun; 25(11):2256-2268. PubMed ID: 27008870
[TBL] [Abstract][Full Text] [Related]
46. Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany.
Hamann U; Liu X; Bungardt N; Ulmer HU; Bastert G; Sinn HP
Eur J Hum Genet; 2003 Jun; 11(6):464-7. PubMed ID: 12774040
[TBL] [Abstract][Full Text] [Related]
47. Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6.
Raponi M; Kralovicova J; Copson E; Divina P; Eccles D; Johnson P; Baralle D; Vorechovsky I
Hum Mutat; 2011 Apr; 32(4):436-44. PubMed ID: 21309043
[TBL] [Abstract][Full Text] [Related]
48. BRCA1 Circos: a visualisation resource for functional analysis of missense variants.
Jhuraney A; Velkova A; Johnson RC; Kessing B; Carvalho RS; Whiley P; Spurdle AB; Vreeswijk MP; Caputo SM; Millot GA; Vega A; Coquelle N; Galli A; Eccles D; Blok MJ; Pal T; van der Luijt RB; Santamariña Pena M; Neuhausen SL; Donenberg T; Machackova E; Thomas S; Vallée M; Couch FJ; Tavtigian SV; Glover JN; Carvalho MA; Brody LC; Sharan SK; Monteiro AN;
J Med Genet; 2015 Apr; 52(4):224-30. PubMed ID: 25643705
[TBL] [Abstract][Full Text] [Related]
49. Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of
Petitalot A; Dardillac E; Jacquet E; Nhiri N; Guirouilh-Barbat J; Julien P; Bouazzaoui I; Bonte D; Feunteun J; Schnell JA; Lafitte P; Aude JC; Noguès C; Rouleau E; Lidereau R; Lopez BS; Zinn-Justin S; Caputo SM;
Mol Cancer Res; 2019 Jan; 17(1):54-69. PubMed ID: 30257991
[No Abstract] [Full Text] [Related]
50. Multifactorial likelihood assessment of BRCA1 and BRCA2 missense variants confirms that BRCA1:c.122A>G(p.His41Arg) is a pathogenic mutation.
Whiley PJ; Parsons MT; Leary J; Tucker K; Warwick L; Dopita B; Thorne H; Lakhani SR; Goldgar DE; Brown MA; Spurdle AB
PLoS One; 2014; 9(1):e86836. PubMed ID: 24489791
[TBL] [Abstract][Full Text] [Related]
51. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
52. ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations.
Brunet J; Gutiérrez-Enríquez S; Torres A; Bérez V; Sanjosé S; Galceran J; Izquierdo A; Menéndez JA; Gumà J; Borràs J
Clin Genet; 2008 May; 73(5):465-73. PubMed ID: 18384426
[TBL] [Abstract][Full Text] [Related]
53. The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity.
Ostrow KL; McGuire V; Whittemore AS; DiCioccio RA
Cancer Genet Cytogenet; 2004 Sep; 153(2):177-80. PubMed ID: 15350310
[TBL] [Abstract][Full Text] [Related]
54. Characterization of a novel large deletion and single point mutations in the BRCA1 gene in a Greek cohort of families with suspected hereditary breast cancer.
Belogianni I; Apessos A; Mihalatos M; Razi E; Labropoulos S; Petounis A; Gaki V; Keramopoulos A; Pandis N; Kyriacou K; Hadjisavvas A; Kosmidis P; Yannoukakos D; Nasioulas G
BMC Cancer; 2004 Sep; 4():61. PubMed ID: 15353005
[TBL] [Abstract][Full Text] [Related]
55. Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model.
Yang Y; Swaminathan S; Martin BK; Sharan SK
Hum Mol Genet; 2003 Sep; 12(17):2121-31. PubMed ID: 12915465
[TBL] [Abstract][Full Text] [Related]
56. Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.
Mirkovic N; Marti-Renom MA; Weber BL; Sali A; Monteiro AN
Cancer Res; 2004 Jun; 64(11):3790-7. PubMed ID: 15172985
[TBL] [Abstract][Full Text] [Related]
57. Molecular and in silico analysis of BRCA1 and BRCA2 variants.
Tommasi S; Pilato B; Pinto R; Monaco A; Bruno M; Campana M; Digennaro M; Schittulli F; Lacalamita R; Paradiso A
Mutat Res; 2008 Sep; 644(1-2):64-70. PubMed ID: 18694767
[TBL] [Abstract][Full Text] [Related]
58. The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript.
Vega A; Campos B; Bressac-De-Paillerets B; Bond PM; Janin N; Douglas FS; Domènech M; Baena M; Pericay C; Alonso C; Carracedo A; Baiget M; Diez O
Hum Mutat; 2001 Jun; 17(6):520-1. PubMed ID: 11385711
[TBL] [Abstract][Full Text] [Related]
59. A Novel Pathogenic BRCA1 Splicing Variant Produces Partial Intron Retention in the Mature Messenger RNA.
Esposito MV; Nunziato M; Starnone F; Telese A; Calabrese A; D'Aiuto G; Pucci P; D'Aiuto M; Baralle F; D'Argenio V; Salvatore F
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 28009814
[TBL] [Abstract][Full Text] [Related]
60. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
